CL2017001736A1 - Anticuerpos anti-cd47 y uso de los mismos. - Google Patents

Anticuerpos anti-cd47 y uso de los mismos.

Info

Publication number
CL2017001736A1
CL2017001736A1 CL2017001736A CL2017001736A CL2017001736A1 CL 2017001736 A1 CL2017001736 A1 CL 2017001736A1 CL 2017001736 A CL2017001736 A CL 2017001736A CL 2017001736 A CL2017001736 A CL 2017001736A CL 2017001736 A1 CL2017001736 A1 CL 2017001736A1
Authority
CL
Chile
Prior art keywords
methods
antibodies
prepare
compositions
diagnostic
Prior art date
Application number
CL2017001736A
Other languages
English (en)
Inventor
Aaron Sato
Ryan Stafford
Junhao Yang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2017001736A1 publication Critical patent/CL2017001736A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>SE PROPORCIONAN AQUÍ COMPOSICIONES, MÉTODOS Y USOS QUE IMPLICAN ANTICUERPOS QUE SE UNEN ESPECÍFICAMENTE A CD47 HUMANO. TAMBIÉN SE PROPORCIONAN USOS Y MÉTODOS, TALES COMO MÉTODOS TERAPÉUTICOS, MÉTODOS DE DIAGNÓSTICO Y MÉTODOS PARA PREPARAR DICHOS ANTICUERPOS.</p>
CL2017001736A 2014-12-30 2017-06-29 Anticuerpos anti-cd47 y uso de los mismos. CL2017001736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462098291P 2014-12-30 2014-12-30

Publications (1)

Publication Number Publication Date
CL2017001736A1 true CL2017001736A1 (es) 2018-03-16

Family

ID=56284963

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001736A CL2017001736A1 (es) 2014-12-30 2017-06-29 Anticuerpos anti-cd47 y uso de los mismos.

Country Status (17)

Country Link
US (2) US10870699B2 (es)
EP (1) EP3240569A4 (es)
JP (2) JP6850255B2 (es)
KR (1) KR102489471B1 (es)
CN (1) CN107530421B (es)
AU (1) AU2015374301B2 (es)
BR (1) BR112017014258A2 (es)
CA (1) CA2972604C (es)
CL (1) CL2017001736A1 (es)
CO (1) CO2017007673A2 (es)
EA (1) EA037654B1 (es)
EC (1) ECSP17041865A (es)
HK (1) HK1245154A1 (es)
MX (1) MX2017008819A (es)
SG (2) SG11201705310TA (es)
WO (1) WO2016109415A1 (es)
ZA (1) ZA201704467B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705310TA (en) 2014-12-30 2017-07-28 Celgene Corp Anti-cd47 antibodies and uses thereof
CN107636014B (zh) * 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
TW201811824A (zh) * 2016-07-06 2018-04-01 美商西建公司 具有低免疫原性之抗體及其用途
IL265605B1 (en) 2016-09-29 2024-02-01 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin structures, a pharmaceutical preparation containing them, their use and methods for their preparation
BR112019008010A2 (pt) 2016-10-20 2019-07-09 I Mab anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
US11779631B2 (en) 2016-11-03 2023-10-10 Pfizer Inc. CD47 blockade therapy by HDAC inhibitors
EP3538557A4 (en) * 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODIES
US11319378B2 (en) 2016-11-18 2022-05-03 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
EP3574009A4 (en) * 2017-01-26 2020-11-25 Zlip Holding Limited CD47 ANTIGEN BINDING UNIT AND ITS USES
WO2018152033A1 (en) * 2017-02-14 2018-08-23 Promab Biotechnologies, Inc. Cd47-car-t cells
MX2019011624A (es) 2017-03-27 2019-12-05 Celgene Corp Metodos y composiciones para la reduccion de la inmunogenicidad.
EP3610022A1 (en) 2017-04-14 2020-02-19 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
US11401329B2 (en) * 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
SG11202001425TA (en) * 2017-08-18 2020-03-30 Ultrahuman Four Ltd Binding agents
CA3044097A1 (en) * 2017-11-10 2019-05-16 I-Mab Fusion proteins containing cd47 antibodies and cytokines
MX2020005463A (es) 2017-12-01 2020-09-07 Seattle Genetics Inc Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
SG11202005216XA (en) * 2017-12-04 2020-07-29 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
AU2019212674A1 (en) * 2018-01-24 2020-09-03 Nanjing Legend Biotech Co., Ltd. Anti-CD47 antibodies that do not cause significant red blood cell agglutination
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
GB201804860D0 (en) * 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
CN112566662A (zh) 2018-06-15 2021-03-26 阿库鲁斯生物科学公司 针对cd47的阻断抗体及其使用方法
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
CN110872348B (zh) * 2018-09-03 2021-09-03 长春金赛药业有限责任公司 人源化抗cd47单克隆抗体及其应用
JP2022500357A (ja) * 2018-10-31 2022-01-04 アイ−マブ バイオファーマ ユーエス リミテッド 新規ｃｄ４７抗体およびその使用方法
JP2022523543A (ja) * 2019-03-06 2022-04-25 ジエンス ヘンルイ メデイシンカンパニー リミテッド 二機能性融合タンパク質及びその医薬的使用
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
KR20220085796A (ko) 2019-10-18 2022-06-22 포티 세븐, 인코포레이티드 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
KR20220103959A (ko) * 2019-10-25 2022-07-25 우시 바이올로직스 아일랜드 리미티드 신규한 항-cd47 항체 및 그 용도
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
KR20220131918A (ko) 2019-12-24 2022-09-29 카나 바이오사이언스, 인코포레이션 다이아실글리세롤 키나제 조절 화합물
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
CA3169523A1 (en) 2020-02-28 2021-09-02 Jaume Pons Transglutaminase-mediated conjugation
JP2023531678A (ja) 2020-06-22 2023-07-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 加齢筋肉、萎縮性筋肉、または異栄養性筋肉の処置のためのｔｓｐ－１阻害物質
AU2021342284A1 (en) * 2020-09-14 2023-04-20 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
US20230365681A1 (en) 2020-10-07 2023-11-16 Celgene Corporation Bispecific antibody treatment of lymphoid malignant neoplasm conditions
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
EP4050029A4 (en) * 2020-12-23 2023-07-12 Guangdong Feipeng Pharmaceutical Co., Ltd ANTIBODIES AGAINST CD47 AND USE THEREOF
WO2022148412A1 (zh) 2021-01-08 2022-07-14 北京韩美药品有限公司 特异性结合cd47的抗体及其抗原结合片段
AU2022235341A1 (en) 2021-03-12 2023-09-21 Mendus B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
WO2024005423A1 (ko) * 2022-06-29 2024-01-04 고려대학교 산학협력단 인간 FCγRS 결합력이 제거된 당화 FC 변이체들
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024015653A1 (en) * 2022-07-10 2024-01-18 Mbrace Therapeutics, Inc. Cell-free methods of recombinant antibody production
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
PT1233987E (pt) 1999-11-29 2009-12-28 Bac Ip B V Imobilização de moléculas de ligação ao antigénio de um domínio
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
BRPI0809026A2 (pt) 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2011004847A1 (ja) 2009-07-07 2011-01-13 一般財団法人化学及血清療法研究所 新規ヒト化抗ヒトα９インテグリン抗体
CA2771336C (en) 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
EP2721073A1 (en) * 2011-06-16 2014-04-23 Novartis AG Soluble proteins for use as therapeutics
WO2013109752A1 (en) * 2012-01-17 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University High affinity sirp-alpha reagents
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
PL2812443T3 (pl) 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
ES2944477T3 (es) 2013-02-06 2023-06-21 Inhibrx Inc Anticuerpos CD47 no reductores de plaquetas y no reductores de glóbulos rojos y métodos de uso de los mismos
JP6463732B2 (ja) * 2013-04-19 2019-02-06 ストロ バイオファーマ， インコーポレイテッド 上昇したレベルの外因性シャペロンを有する細胞抽出物を用いる細菌無細胞合成系における生物活性のあるタンパク質の発現
SG11201705310TA (en) 2014-12-30 2017-07-28 Celgene Corp Anti-cd47 antibodies and uses thereof
NZ740686A (en) 2015-09-18 2021-12-24 Arch Oncology Inc Therapeutic cd47 antibodies
CA2999277A1 (en) 2015-09-21 2017-03-30 Surface Oncology, Inc. Anti-cd47 antibodies and methods of use

Also Published As

Publication number Publication date
ZA201704467B (en) 2019-09-25
EA201791485A1 (ru) 2018-02-28
US11787860B2 (en) 2023-10-17
US10870699B2 (en) 2020-12-22
KR20170100652A (ko) 2017-09-04
CO2017007673A2 (es) 2018-01-05
US20210054070A1 (en) 2021-02-25
CN107530421B (zh) 2021-07-20
JP6850255B2 (ja) 2021-03-31
AU2015374301A1 (en) 2017-07-20
MX2017008819A (es) 2018-03-14
JP2021048858A (ja) 2021-04-01
KR102489471B1 (ko) 2023-01-18
US20170369572A1 (en) 2017-12-28
EP3240569A4 (en) 2018-05-30
SG11201705310TA (en) 2017-07-28
AU2015374301B2 (en) 2021-02-11
SG10202007176TA (en) 2020-08-28
EA037654B1 (ru) 2021-04-27
CN107530421A (zh) 2018-01-02
CA2972604A1 (en) 2016-07-07
EP3240569A1 (en) 2017-11-08
CA2972604C (en) 2023-07-04
JP2018506964A (ja) 2018-03-15
ECSP17041865A (es) 2017-08-31
HK1245154A1 (zh) 2018-08-24
BR112017014258A2 (pt) 2018-03-06
WO2016109415A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
CL2017001736A1 (es) Anticuerpos anti-cd47 y uso de los mismos.
CL2016002252A1 (es) Anticuerpos anti-egfrviii y usos de los mismos
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
PE20200617A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39
CL2016002055A1 (es) Uso de compuestos 3-isoxazolidinonas como herbicidas selectivos
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
BR112016021626A2 (pt) indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
BR112016030968A2 (pt) análogos de pridopidina, preparação e uso destes
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CO7061078A2 (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
CR20150549A (es) Compuestos heterocíclicos y sus usos
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
SV2016005264A (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas
BR112017028008A2 (pt) novas 3-fenilpirrolidinas-2, 4-dionas substituídas por alquinila e uso destas como herbicidas
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
GT201600252A (es) Derivados de naftiridinadiona